Colossal Raises $200M for De-Extinction Efforts

Colossal Biosciences, a biotech startup focused on de-extinction, has raised $200 million in a Series C funding round, elevating its valuation to $10.2 billion. This significant fundraising, led by TWG Global and involving high-profile investors like Mark Walter and Thomas Tull, supports the company's mission to resurrect extinct species such as the woolly mammoth, dodo, and Tasmanian tiger by 2028. Colossal's approach involves editing mammoth genes into Asian elephant cells and has gained support from celebrities like Tom Brady and Tiger Woods, though some scientists express skepticism about the feasibility and ethics of reintroducing these species. The company's efforts extend beyond de-extinction, contributing to biodiversity and ecosystem restoration while innovating technologies with broader applications, including human healthcare. Despite the ambitious goals, critics question the ethical and practical implications of reviving species that went extinct thousands of years ago.